Rituximab with ABVD vs ABVD for advanced stage high-risk classical Hodgkin lymphoma: a randomized phase II study.

Paolo Strati,Michelle A Fanale,Yasuhiro Oki,Francesco Turturro,Luis E Fayad,Nancy L Bartlett,Douglas E Gladstone,Yvette L Kasamon,Carol S Portlock,Wyndham H Wilson,Andre Goy,Anas Younes,Hun Ju Lee

HAEMATOLOGICA（2019）

引用 8|浏览28

暂无评分

摘要

Based on several randomized studies comparing doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with other multi-drug regimens, ABVD is the standard of care for newly diagnosed, advanced stage, classical Hodgkin lymphoma (cHL).[1][1] While the cure rate with ABVD approximates 75% in

查看译文

关键词

ABVD,HL,RITUXIMAB

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要